• Top Stories
  • Interviews
  • Business
  • Finance
  • Banking
  • Technology
  • Investing
  • Trading
  • Videos
  • Awards
  • Magazines
  • Headlines
  • Trends
Close Search
00
GBAF LogoGBAF Logo
  • Top Stories
  • Interviews
  • Business
  • Finance
  • Banking
  • Technology
  • Investing
  • Trading
  • Videos
  • Awards
  • Magazines
  • Headlines
  • Trends
GBAF Logo
  • Top Stories
  • Interviews
  • Business
  • Finance
  • Banking
  • Technology
  • Investing
  • Trading
  • Videos
  • Awards
  • Magazines
  • Headlines
  • Trends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking and Finance Review

Global Banking & Finance Review

Company

    GBAF Logo
    • About Us
    • Profile
    • Wealth
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2025 GBAF Publications Ltd - All Rights Reserved.

    ;
    Editorial & Advertiser disclosure

    Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Research Reports

    Posted By Coherent Market Insights

    Posted on September 14, 2021

    Featured image for article about Research Reports

    Antibacterial drugs are widely used to treat and prevent infectious diseases and are categorized into seven major classes, such as β-Lactams, phenicols, macrolides, quinolones, sulfonamides, tetracyclines, and aminoglycosides, based on their molecular structure. Antibacterial drugs destroy or slow down the growth of bacteria. These medications are also used to treat urinary infections caused by S. aureus, E. coli, Streptococcus pyogenes, and other bacterial infections.

    The PDF for the study can be requested using the following link: https://www.coherentmarketinsights.com/insight/request-pdf/177

    They include a range of powerful drugs used to treat diseases caused by bacteria. Antibiotics cannot treat viral infections, such as cold, flu, and most coughs. Antibacterial drugs play a major role in advanced healthcare, as they are widely used to treat infectious diseases, such as tuberculosis, malaria, typhoid, leprosy, hepatitis B, HIV/AIDS, and others. Thus, there is an increasing demand for antibacterial drugs worldwide.

    Key Market Drivers:

    Increasing prevalence of infectious diseases around the world is expected to boost the growth of the antibacterial drugs market over the forecast period. Worldwide, tuberculosis is one of the top ten causes of death. For instance, according to the World Health Organization (WHO), in 2019, around 10 million people fell ill with tuberculosis worldwide. Tuberculosis is present in all countries and age groups.

    Moreover, increasing incidences of bacterial infections worldwide is expected to drive growth of the antibacterial drugs market. For instance, according to the Centers for Disease Control and Prevention (CDC), each year, more than 2.8 million antibiotic-resistant infections occur in the United States, and more than 35,000 people die as a result.

    COVID-19 Impact Analysis:

    The pandemic had a temporary or minimal impact on the antibiotics and antimicrobials market or its growth during the forecast period. On the other hand, worldwide, there was high demand for antimicrobial drugs during the pandemic, such as cefuroxime, meropenem, vancomycin, cefepime, ceftazidime, ciprofloxacin, piperacillin/tazobactam, benzylpenicillin, gentamicin, ampicillin, amoxicillin, erythromycin, ceftriaxone, clarithromycin, doxycycline, azithromycin, and amoxicillin-clavulanic acid, among others.

    These antimicrobials were recommended for use in the management of COVID-19. Moreover, pharmaceutical companies responded to the growing demand for antibiotics and other essential medicines for patients during COVID-19. This in turn is expected to augment the growth of the antibacterial drugs market.

    Key Takeaways

    • The antibacterial drugs market is expected to exhibit a CAGR of XX % during the forecast period owing to the increasing launches and approvals of new antibacterial drugs across the world. For instance, in June 2020, the U.S. Food and Drug Administration (FDA) approved Recarbrio (antibacterial drug) to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years of age and older.

    • Among regions, North America is expected to witness robust growth in the antibacterial drugs market due to the increasing incidences of infectious diseases, such as tuberculosis, salmonella, Lyme disease, and meningococcal disease, in the region, especially in the U.S. According to CDC, in 2018, around 9,025 new cases of tuberculosis, 60,999 new cases of salmonella, 33,666 new cases of Lyme disease, and 327 cases of meningococcal disease were reported in the United States.

    Top Key Players Include In Antibacterial Drugs Market: Novartis AG, Allergan, Bristol Myers Squibb Company, AstraZeneca, Johnson and Johnson, Merck & Co., Inc., GlaxoSmithKline Plc. (GSK), Sanofi SA, Bayer AG, and Pfizer Inc.

    Buy This Research Study Report For Quick Access With Flat US $ 2000 Off@ https://www.coherentmarketinsights.com/promo/buynow/177

    Contact Us

    Mr. Shah
    Coherent Market Insights
    1001 4th Ave, #3200
    Seattle, WA 98154
    Phone: US +12067016702 / UK +4402081334027
    Email: [email protected]

    The post Antibacterial Drugs Market by 2021 Trends Progresses for Huge Profits at US$ 44,063.3 Mn by Global Demand to 2027 | Coherent Market Insights appeared first on Gatorledger.

    Antibacterial drugs are widely used to treat and prevent infectious diseases and are categorized into seven major classes, such as β-Lactams, phenicols, macrolides, quinolones, sulfonamides, tetracyclines, and aminoglycosides, based on their molecular structure. Antibacterial drugs destroy or slow down the growth of bacteria. These medications are also used to treat urinary infections caused by S. aureus, E. coli, Streptococcus pyogenes, and other bacterial infections.

    The PDF for the study can be requested using the following link: https://www.coherentmarketinsights.com/insight/request-pdf/177

    They include a range of powerful drugs used to treat diseases caused by bacteria. Antibiotics cannot treat viral infections, such as cold, flu, and most coughs. Antibacterial drugs play a major role in advanced healthcare, as they are widely used to treat infectious diseases, such as tuberculosis, malaria, typhoid, leprosy, hepatitis B, HIV/AIDS, and others. Thus, there is an increasing demand for antibacterial drugs worldwide.

    Key Market Drivers:

    Increasing prevalence of infectious diseases around the world is expected to boost the growth of the antibacterial drugs market over the forecast period. Worldwide, tuberculosis is one of the top ten causes of death. For instance, according to the World Health Organization (WHO), in 2019, around 10 million people fell ill with tuberculosis worldwide. Tuberculosis is present in all countries and age groups.

    Moreover, increasing incidences of bacterial infections worldwide is expected to drive growth of the antibacterial drugs market. For instance, according to the Centers for Disease Control and Prevention (CDC), each year, more than 2.8 million antibiotic-resistant infections occur in the United States, and more than 35,000 people die as a result.

    COVID-19 Impact Analysis:

    The pandemic had a temporary or minimal impact on the antibiotics and antimicrobials market or its growth during the forecast period. On the other hand, worldwide, there was high demand for antimicrobial drugs during the pandemic, such as cefuroxime, meropenem, vancomycin, cefepime, ceftazidime, ciprofloxacin, piperacillin/tazobactam, benzylpenicillin, gentamicin, ampicillin, amoxicillin, erythromycin, ceftriaxone, clarithromycin, doxycycline, azithromycin, and amoxicillin-clavulanic acid, among others.

    These antimicrobials were recommended for use in the management of COVID-19. Moreover, pharmaceutical companies responded to the growing demand for antibiotics and other essential medicines for patients during COVID-19. This in turn is expected to augment the growth of the antibacterial drugs market.

    Key Takeaways

    • The antibacterial drugs market is expected to exhibit a CAGR of XX % during the forecast period owing to the increasing launches and approvals of new antibacterial drugs across the world. For instance, in June 2020, the U.S. Food and Drug Administration (FDA) approved Recarbrio (antibacterial drug) to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years of age and older.

    • Among regions, North America is expected to witness robust growth in the antibacterial drugs market due to the increasing incidences of infectious diseases, such as tuberculosis, salmonella, Lyme disease, and meningococcal disease, in the region, especially in the U.S. According to CDC, in 2018, around 9,025 new cases of tuberculosis, 60,999 new cases of salmonella, 33,666 new cases of Lyme disease, and 327 cases of meningococcal disease were reported in the United States.

    Top Key Players Include In Antibacterial Drugs Market: Novartis AG, Allergan, Bristol Myers Squibb Company, AstraZeneca, Johnson and Johnson, Merck & Co., Inc., GlaxoSmithKline Plc. (GSK), Sanofi SA, Bayer AG, and Pfizer Inc.

    Buy This Research Study Report For Quick Access With Flat US $ 2000 Off@ https://www.coherentmarketinsights.com/promo/buynow/177

    Contact Us

    Mr. Shah
    Coherent Market Insights
    1001 4th Ave, #3200
    Seattle, WA 98154
    Phone: US +12067016702 / UK +4402081334027
    Email: [email protected]

    The post Antibacterial Drugs Market by 2021 Trends Progresses for Huge Profits at US$ 44,063.3 Mn by Global Demand to 2027 | Coherent Market Insights appeared first on Gatorledger.

    Recommended for you

    • Thumbnail for recommended article

    • Thumbnail for recommended article

    • Thumbnail for recommended article

    Why waste money on news and opinions when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe